

Leading Driver In The Oral Hypoglycemic Agents Market 2025: Rising Prevalence Of Type 2 Diabetes Driving Growth

The Business Research Company's Oral Hypoglycemic Agents Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, June 20, 2025

/EINPresswire.com/ -- The [oral](#)

[hypoglycemic agents market size](#) saw

robust growth in recent years. In 2024, it stood at \$57.04 billion, but by 2025, it is estimated to increase to \$60.15 billion, showcasing a compound annual growth rate CAGR of 5.5%. This exceptional growth in the historic period has been driven by several crucial factors, including increasing prevalence of type 2 diabetes, growing geriatric population, rising awareness about

diabetes management, expanding healthcare access in emerging markets, and preference for oral therapies over injectable forms.



The Business Research Company's Oral Hypoglycemic Agents Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034"

The Business Research Company

What Is The Projected Future Growth Of The Oral Hypoglycemic Agents Market Size?

The oral hypoglycemic agents market isn't forecasted to plateau anytime soon, with projections indicating strong growth in the next few years. By 2029, the oral hypoglycemic agents market size is expected to rise to \$73.69 billion, displaying a CAGR of 5.2%. This anticipated

growth in the market can be attributed to the escalating demand for combination therapies, supportive government healthcare policies, adoption of telemedicine for diabetes care, increased investments in research and development of diabetes treatments, and a rising focus on personalized diabetes treatments.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24347&type=smp>

The Business
Research Company

The Business Research Company



What Are The Key Drivers Propelling The Growth Of The Oral Hypoglycemic Agents Market?
Delving deeper into the forecast period, there are several key trends that are expected to shape the oral hypoglycemic agents market's trajectory. These include the development of innovative oral antidiabetics, the creation of fixed-dose combinations, advancements in drug formulation technology, a concentrated effort toward reducing drug side effects, and the integration of digital health tools for glucose monitoring.

Closely tied to these market dynamics is the expected rise in type 2 diabetes prevalence, which will serve as a significant propellant for growth in the oral hypoglycemic agents market. Type 2 diabetes, a chronic metabolic disorder characterized by the body's inefficient use of insulin, leads to elevated blood glucose levels. The ever-increasing prevalence of sedentary lifestyles, which significantly reduce physical activity leading to obesity and insulin resistance, are leading to a rise in type 2 diabetes cases. Hence, oral hypoglycemic agents, which help manage type 2 diabetes by lowering blood glucose levels through various mechanisms, are experiencing growing demand.

What Key Player Strategies Are Driving The Oral Hypoglycemic Agents Market?

Major players operating within the oral hypoglycemic agents market include Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd. These industry leaders are concentrating on the development of advanced therapeutic solutions, such as dipeptidyl peptidase-4 DPP-4 inhibitors, to improve blood sugar control in patients with Type 2 diabetes.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/oral-hypoglycemic-agents-global-market-report>

How Is The [Oral Hypoglycemic Agents Market Segmented?](#)

The oral hypoglycemic agents market report covers a comprehensive segmentation –

By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy.

By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations.

By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities.

By End users: Hospitals, Clinics.

What Are The Regional Insights In The Oral Hypoglycemic Agents Market?

Recent developments have increased regional insights into the market. North America was the largest region in the oral hypoglycemic agents market in 2024, with Asia-Pacific projected to be the fastest-growing region in the forecast period. The report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By [The Business Research Company](#):

Oral Cancer Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report>

Oral Care Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/oral-care-global-market-report>

Oral Contraceptive Pills Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report>

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info

This press release can be viewed online at: <https://www.einpresswire.com/article/823978946>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.